Trial · NCT01640964
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline of the Blood Flow for the Total Renal Arteries (Study Part A (Serelaxin Treatment Group Only)) | Part A: Serelaxin (RLX030) | 0.438 | 95% Confidence Interval 0.274 to 0.601 | L/min | |
| Change From Baseline of the Portal Pressure Gradient (PPG) (Study Part B) | Part B: Serelaxin (RLX030) | -1.2 | 95% Confidence Interval -6.1 to 3.7 | mmHg | |
| Change From Baseline of the Blood Flow for the Total Renal Arteries (Study Part A (Terlipressin Acetate Group Only)) | Part A: Terlipressin Acetate | 0.059 | 95% Confidence Interval -0.045 to 0.164 | L/min | |
| Change From Baseline of the Blood Flow for the Hepatic Artery (Study Part A (Serelaxin Treatment Group Only)) | Part A: Serelaxin (RLX030) | 0.084 | 95% Confidence Interval -0.020 to 0.187 | L/min | |
| Change From Baseline of the Blood Flow for the Superior Mesenteric Artery (Study Part A (Serelaxin Treatment Group Only)) | Part A: Serelaxin (RLX030) | 0.002 | 95% Confidence Interval -0.087 to 0.090 | L/min | |
| Change From Baseline of the Blood Flow for the Descending Thoracic Aorta (Study Part A (Serelaxin Treatment Group Only)) | Part A: Serelaxin (RLX030) | 0.293 | 95% Confidence Interval 0.059 to 0.527 | L/min | |
| Change From Baseline of the Blood Flow for the Portal Vein (Study Part A (Serelaxin Treatment Group Only)) | Part A: Serelaxin (RLX030) | -0.091 | 95% Confidence Interval -0.204 to 0.023 | L/min | |
| Change From Baseline of the Portal Vein Pressure (PVP) (Study Part B) | Part B: Serelaxin (RLX030) | -3.7 | 95% Confidence Interval -8.8 to 1.4 | mmHg | |
| Number of Patients With Total Adverse Events, Serious Adverse and Death as Assessment of Safety and Tolerability of Serelaxin | Part A: Serelaxin (RLX030) | Any adverse event | 3 | Patients | |
| Number of Patients With Total Adverse Events, Serious Adverse and Death as Assessment of Safety and Tolerability of Serelaxin | Part B: Serelaxin (RLX030) | Any adverse event | 3 | Patients | |
| Number of Patients With Total Adverse Events, Serious Adverse and Death as Assessment of Safety and Tolerability of Serelaxin | Part A: Serelaxin (RLX030) | Serious Adverse Events | 1 | Patients | |
| Number of Patients With Total Adverse Events, Serious Adverse and Death as Assessment of Safety and Tolerability of Serelaxin | Part B: Serelaxin (RLX030) | Serious Adverse Events | 2 | Patients | |
| Number of Patients With Total Adverse Events, Serious Adverse and Death as Assessment of Safety and Tolerability of Serelaxin | Part A: Serelaxin (RLX030) | Death | 0 | Patients | |
| Number of Patients With Total Adverse Events, Serious Adverse and Death as Assessment of Safety and Tolerability of Serelaxin | Part B: Serelaxin (RLX030) | Death | 0 | Patients |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01640964/results